Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jesse Cooper

Nurse Practitioner, Psychiatric/Mental Health Wasilla, AK Nurse Practitioner

NPI 1366058224 CMS profile 10799103

1981 E Palmer Wasilla Hwy Ste 200, Wasilla, AK 99654

Open in the dashboard

General payments

$2,817

129 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jesse Cooper of Wasilla, AK is reported in the CMS Open Payments database as having received $2,817 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $311 14
2024 General $557 23
2023 General $910 37
2022 General $523 26
2021 General $516 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jesse Cooper
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Jesse Cooper were reported at $311. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Jesse Cooper Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $516 $166 $54–$482 $132
2022 $523 $195 $66–$559 $149
2023 $910 $233 $82–$673 $160
2024 $557 $236 $84–$688 $164
2025 $311 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $691 27 payments
  2. Astellas Pharma US Inc $358 13 payments
  3. ITI, Inc. $266 13 payments
  4. AstraZeneca Pharmaceuticals LP $222 12 payments
  5. Novo Nordisk Inc $108 6 payments
  6. Neurocrine Biosciences, Inc. $103 4 payments
  7. GlaxoSmithKline, LLC. $97 5 payments
  8. Janssen Pharmaceuticals, Inc $94 5 payments
  9. Pfizer Inc. $90 5 payments
  10. Lilly USA, LLC $87 4 payments
  11. Other $701 35 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,742 128 payments
  2. Education $75 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $339 11 payments
  2. Veozah $214 9 payments
  3. UBRELVY $172 8 payments
  4. CAPLYTA Psychiatry $172 8 payments
  5. FARXIGA $152 8 payments
  6. INGREZZA $103 4 payments
  7. NURTEC ODT $103 5 payments
  8. VRAYLAR Neuroscience $98 4 payments
  9. CAPLYTA Psychiatry $94 5 payments
  10. TRELEGY ELLIPTA $76 4 payments
  11. Other $1,743 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$18,795

Medicare's payments for the services billed

Medicare patients

46

Average age 66

Services billed

186

30 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 61%
Depression 37%
Ischemic heart disease 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $109
$109 — —
Veozah
  • Astellas Pharma US Inc $103
$103 — —
VRAYLAR
  • AbbVie, Inc. $84
$84 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $45
$45 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record